Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
Andrea Necchi, Daniele Raggi, Andrea Gallina, Jeffrey S. Ross, Elena Farè, Patrizia Giannatempo, Laura Marandino, Maurizio Colecchia, Roberta Lucianò, Marco Bianchi, Renzo Colombo, Andrea Salonia, Giorgio Gandaglia, Nicola Fossati, Marco Bandini, Filippo Pederzoli, Umberto Capitanio, Francesco Montorsi, Joep J. de Jong, Ryan Dittamore, Yang Liu, Elai Davicioni, Joost L. Boormans, Alberto Briganti, Peter C. Black, Ewan A. Gibb
Topics & Concepts
MedicinePembrolizumabBladder cancerPathologicalNeoadjuvant therapyOncologyComplete responseInfiltration (HVAC)SubtypingImmune systemPathologyInternal medicineImmunotherapyUrologyCancerChemotherapyImmunologyBreast cancerPhysicsThermodynamicsComputer scienceProgramming languageBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis